MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Pacira BioSciences Net Debt 2011-2026 | PCRX
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Pacira BioSciences
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 317 M | 378 M | 594 M | -238 M | 220 M | 442 M | 158 M | 222 M | 209 M | 48.9 M | 65.6 M | 86.4 M | 46 M | -20.6 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 594 M | -238 M | 181 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Drug manufacturers industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
-6.59 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Alimera Sciences
ALIM
|
-11.2 M | - | - | $ 142 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-11.1 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
-676 K | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-22.5 M | - | 0.86 % | $ 117 M | USA |
 |
Canopy Growth Corporation
CGC
|
193 M | $ 0.97 | 2.36 % | $ 104 M |  Canada |
 |
Aurora Cannabis
ACB
|
285 M | $ 3.31 | 1.53 % | $ 86.3 M | Canada |
 |
China Pharma Holdings
CPHI
|
-4.73 M | $ 0.63 | 16.11 % | $ 11 M |  China |
 |
Catalent
CTLT
|
4.58 B | - | - | $ 11.5 B | USA |
 |
Athenex
ATNX
|
-28.3 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-49.7 M | - | - | $ 2.06 B |  France |
 |
Cronos Group
CRON
|
-1.07 B | $ 2.52 | 5.44 % | $ 1.31 B | Canada |
 |
DURECT Corporation
DRRX
|
-10.4 M | - | - | $ 50.1 M | USA |
 |
Emergent BioSolutions
EBS
|
338 M | $ 8.05 | -1.71 % | $ 412 M | USA |
 |
Endo International plc
ENDP
|
7.37 B | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
-2.96 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-931 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-150 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
-12.7 M | $ 3.05 | 7.77 % | $ 42.9 M | USA |
 |
Bausch Health Companies
BHC
|
21.1 B | $ 5.1 | 1.8 % | $ 1.86 B | Canada |
 |
Harrow Health
HROW
|
178 M | $ 34.0 | 2.16 % | $ 1.25 B | USA |
 |
Assertio Holdings
ASRT
|
29.1 M | $ 14.0 | 4.71 % | $ 89.6 M | USA |
 |
OptiNose
OPTN
|
-72.2 M | - | - | $ 1.08 B | USA |
 |
Evolus
EOLS
|
94.8 M | $ 4.68 | 0.86 % | $ 302 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
2.43 M | - | -39.89 % | $ 27.7 M | USA |
 |
OrganiGram Holdings
OGI
|
90.7 M | $ 1.36 | - | $ 402 M | Canada |
 |
PetIQ
PETQ
|
329 M | - | 1.64 % | $ 400 M | USA |
 |
PLx Pharma
PLXP
|
-21.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
ProPhase Labs
PRPH
|
-6.41 M | - | - | $ 5.07 M | USA |
 |
Jupiter Wellness
JUPW
|
-21.7 K | - | - | $ 33.6 M | USA |
 |
Radius Health
RDUS
|
-111 M | - | - | $ 1.42 B | USA |
 |
Relmada Therapeutics
RLMD
|
-2.5 M | $ 5.86 | -3.46 % | $ 231 M | USA |
 |
Rockwell Medical
RMTI
|
691 K | $ 1.02 | -2.86 % | $ 23.8 M | USA |
 |
Lannett Company
LCI
|
529 M | - | 1.15 % | $ 7.11 M | USA |
 |
Sundial Growers
SNDL
|
-28.4 M | $ 1.36 | 0.74 % | $ 3.37 M | Canada |
 |
SCYNEXIS
SCYX
|
-19.1 M | $ 0.88 | -6.09 % | $ 43.9 M | USA |
 |
Solid Biosciences
SLDB
|
-38.7 M | $ 7.14 | 1.56 % | $ 625 M | USA |
 |
Organogenesis Holdings
ORGO
|
-131 M | $ 2.47 | 3.65 % | $ 325 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-146 M | - | - | $ 193 M | Canada |
 |
Perrigo Company plc
PRGO
|
3.1 B | $ 9.57 | 3.46 % | $ 1.33 B | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-5.29 M | $ 2.55 | 4.94 % | $ 3.16 M | USA |
 |
Tilray
TLRY
|
14.4 M | $ 6.45 | 3.86 % | $ 3.99 B | Canada |
 |
Recro Pharma
REPH
|
-6.65 M | - | -4.76 % | $ 65.3 M | USA |
 |
TherapeuticsMD
TXMD
|
3.68 M | $ 2.31 | 3.12 % | $ 24.1 M | USA |
 |
Veru
VERU
|
-20.9 M | $ 2.3 | 1.32 % | $ 310 M | USA |
 |
Viatris
VTRS
|
16.8 B | $ 13.29 | 0.68 % | $ 16 B | USA |
 |
cbdMD
YCBD
|
-521 K | $ 0.76 | 11.88 % | $ 3.28 M | USA |
 |
Tricida
TCDA
|
-7.08 M | - | - | $ 3.25 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-50.3 M | - | - | $ 55.5 M | USA |